NexImmune, Inc. (Nasdaq: NEXI) Announces IND Clearance by the US FDA for NEXI-003 for the Treatment of HPV-Related
[mstock id=”73007″ asset=”nexi”]
NexImmune gains aftermarket on IND clearance for NEXI-003 to treat HPV-related cancers
- First IND for NexImmune’s AIM nanoparticle platform in solid tumors
- IND clearance enables commencement of a clinical trial to evaluate NEXI-003, an autologous antigen-specific T cell product (CD3+/CD4-), in patients with relapsed or refractory human papillomavirus (HPV)-related cancers
GAITHERSBURG, Md., July 14, 2022 (GLOBE NEWSWIRE) — NexImmune, Inc. (Nasdaq:NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, has received IND clearance for the Company’s first cellular therapy product candidate addressing solid tumors. NEXI-003, an autologous antigen-specific T cell product (CD3+/CD4-), is being developed for patients with relapsed or refractory human papillomavirus (HPV)-related cancers.